The American Society of Hematology (ASH) 65th Annual Meeting & Exposition 2023 is Dec. 9-12 in San Diego, and Baylor Scott & White researchers contributed insightful results to be shared at the conference. ASH is the world's leading provider of hematology education, offering a wide array of educational opportunities to clinicians and scientists.

Baylor University Medical Center at Dallas, part of Baylor Scott & White Health, is a recognized leader in hematology oncology with 40 years of experience in blood and marrow transplant and one of the first North Texas providers to offer adult commercial use of chimeric antigen receptor T-cell therapy, or CAR-T. Learn more about Baylor University Medical Center's comprehensive cancer program and research at CancerUpdate.BSWhealth.com.

A list of Baylor Scott & White abstracts can be found below. Additional details about the ASH meeting are on the event website.

FEATURED PRESENTATIONS AND SESSIONS HIGHLIGHTING RESEARCH IN HEMATOLOGY

SATURDAY, DECEMBER 9, 2023

PRESENTATION: I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

  • Co-Author: Nebu Koshy, MD

  • Time: 5:30-7:30 p.m.

SUNDAY, DECEMBER 10, 2023

PRESENTATION: I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

  • Co-Author: Nebu Koshy, MD

  • Time: 9:30-11:00 a.m.

POSTER: High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

  • Co-Author: Nebu Koshy, MD

  • Time: 6:00-8:00 p.m.

POSTER: Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

  • Co-Author: Moshe Levy, MD

  • Time: 6:00-8:00 p.m.

POSTER: Asciminib (ASC) Once-Daily (QD) Dosing Demonstrates Comparable Tolerability and Efficacy to Twice-Daily (BID) Dosing: Results from the ASC in Monotherapy 4 CML (AIM4CML) Study in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

  • Co-Author: Moshe Levy, MD

  • Time: 6:00-8:00 p.m.

MONDAY, DECEMBER 11, 2023

PRESENTATION: AsCas12a Gene Editing of HBG1/2 Promoters with EDIT-301 Results in Rapid and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

  • Co-Author: Luis Pineiro, MD

  • Time: 6:00-8:00 p.m.

POSTER: Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution Program: Oral and Poster Abstracts

  • Co-Author: Medhat Askar, MD, PhD

  • Time: 6:00-8:00 p.m.

POSTER: Real-World Treatment Patterns and Outcomes in Patients with Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Study Design

  • Co-Author: Moshe Levy, MD

  • Time: 6:00-8:00 p.m.

© 2024 Baylor Scott & White Health. All Rights Reserved.
Privacy and Patient Rights Terms of Use Notice of Non-Discrimination
3500 Gaston Ave., Dallas, TX 75246-2017 | 1.844.BSW.DOCS (1.844.279.3627)